48 results
Page 2 of 3
8-K
EX-10.1
i3503yrn
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-99.1
bybx4
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
424B5
geqboch7uu3nqbd lre
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
pbzxd9g1u830y
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
1rxrrqj f156qprn
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
7md46kczphc10dfr
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
0ia8mbj0mdo j6bnc
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.2
oef3reyyp8qbf8w43t
23 Nov 20
Consolidated Financial Statements
12:00am
424B3
jmju53v7 9z
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
wu5tmjjr4ye 2h4
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
2jcig
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
c0yzl4p2huqjrkfl
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
0g13zxk
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.4
m542jxim90vb9qxl7h0k
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.2
51xrw6rqma
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm